NUVL
Nuvalent, Inc.
NASDAQ · USHealthcareBiotechnology
$123.96+0.00%
Price as of Jul 14, 2026
NUVL growth
Nuvalent, Inc. growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- —
- EBITDA
- -7.1%
- EBIT
- -36.1%
- EPS
- -38.0%
- Free cash flow
- -53.5%
- Operating cash flow
- -53.5%
Forward estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +31.5%
Three-year CAGR
- Revenue
- —
- EBITDA
- —
- EBIT
- -47.8%
- Net income
- -63.1%
- EPS
- -48.9%
- Free cash flow
- -48.7%
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.